Please login to the form below

Not currently logged in
Email:
Password:

CytomX appoints Rachel Humphrey chief medical officer

Former VP of Eli Lilly and AstraZeneca joins the company

CytomX Therapeutics has appointed Dr Rachel Humphrey as chief medical officer.

Humphrey, who has served on the board of the directors at CytomX since March this year, was formerly VP and head of immuno-oncology at both Eli Lilly and AstraZeneca, supervising the development of numerous agents.

She said: “Since joining the CytomX board of directors in March, I have been able to see at first-hand the tremendous power of the Probody platform.

“I am excited to now be joining the management team to help build a great company that has the potential to make a real difference for patients.”

Sean McCarthy, CEO of CytomX, said: “We were thrilled to have Rachel join the board earlier this year, and having her now transition to the management team will allow us to benefit even more from her decades of experience in successful oncology product development and registration.”

Before her time at AZ and Eli Lilly, Humphrey was also VP of product development at Bristol-Myers Squibb where she led all aspects of clinical development of the skin-cancer drug Yervoy (ipilimumab).

Humphrey also spent time at Bayer where she oversaw the early and late stage clinical development of the renal cell carcinoma treatment Nexavar (sorafenib).

28th August 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics